Last reviewed · How we verify
dehydroepiandrosterone crystalline fine powder
dehydroepiandrosterone crystalline fine powder is a Small molecule drug developed by Meir Medical Center. It is currently in Phase 1 development.
At a glance
| Generic name | dehydroepiandrosterone crystalline fine powder |
|---|---|
| Sponsor | Meir Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dehydroepiandrosterone crystalline fine powder CI brief — competitive landscape report
- dehydroepiandrosterone crystalline fine powder updates RSS · CI watch RSS
- Meir Medical Center portfolio CI
Frequently asked questions about dehydroepiandrosterone crystalline fine powder
What is dehydroepiandrosterone crystalline fine powder?
dehydroepiandrosterone crystalline fine powder is a Small molecule drug developed by Meir Medical Center.
Who makes dehydroepiandrosterone crystalline fine powder?
dehydroepiandrosterone crystalline fine powder is developed by Meir Medical Center (see full Meir Medical Center pipeline at /company/meir-medical-center).
What development phase is dehydroepiandrosterone crystalline fine powder in?
dehydroepiandrosterone crystalline fine powder is in Phase 1.